Myriad Genetics (NASDAQ:MYGN – Get Rating) had its price target upped by SVB Leerink from $26.00 to $30.00 in a research note published on Friday, Marketbeat.com reports. They currently have a market perform rating on the stock.
A number of other equities analysts have also weighed in on MYGN. Cowen set a $25.00 target price on Myriad Genetics in a research note on Tuesday, July 19th. StockNews.com lowered Myriad Genetics from a buy rating to a hold rating in a research note on Wednesday, July 13th. TheStreet lowered Myriad Genetics from a c- rating to a d+ rating in a research note on Friday, June 3rd. Finally, The Goldman Sachs Group decreased their target price on Myriad Genetics from $26.00 to $23.00 and set a sell rating on the stock in a research note on Tuesday, April 19th.
Get
Myriad Genetics alerts:
Myriad Genetics Stock Performance
NASDAQ:MYGN opened at $27.12 on Friday. Myriad Genetics has a 52-week low of $16.02 and a 52-week high of $36.95. The firm has a market cap of $2.18 billion, a price-to-earnings ratio of -113.00 and a beta of 1.70. The business's fifty day moving average is $20.77 and its 200 day moving average is $22.84.
Myriad Genetics (NASDAQ:MYGN – Get Rating) last released its quarterly earnings data on Thursday, August 4th. The company reported $0.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.01 by $0.03. The company had revenue of $179.30 million for the quarter, compared to analyst estimates of $170.05 million. Myriad Genetics had a negative return on equity of 3.44% and a negative net
margin of 2.62%. The firm's revenue for the quarter was down 5.3% compared to the same quarter last year. During the same period in the previous year, the company posted $0.03 EPS. Equities analysts predict that Myriad Genetics will post -0.33 EPS for the current fiscal year.
Insider Transactions at Myriad Genetics
In other news, Director Daniel K. Spiegelman sold 6,424 shares of the company's stock in a transaction dated Monday, June 6th. The stock was sold at an average price of $19.25, for a total value of $123,662.00. Following the completion of the transaction, the director now directly owns 33,980 shares in the company, valued at approximately $654,115. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 1.80% of the company's stock.
Institutional Investors Weigh In On Myriad Genetics
Several institutional investors have recently bought and sold shares of the stock. Baird Financial Group Inc. boosted its holdings in Myriad Genetics by 2.6% during the 2nd quarter. Baird Financial Group Inc. now owns 15,662 shares of the company's stock valued at $285,000 after acquiring an additional 394 shares during the period. HighTower Advisors LLC boosted its holdings in Myriad Genetics by 1.7% during the 4th quarter. HighTower Advisors LLC now owns 25,264 shares of the company's stock valued at $700,000 after acquiring an additional 433 shares during the period. Mutual of America Capital Management LLC boosted its holdings in Myriad Genetics by 4.8% during the 4th quarter. Mutual of America Capital Management LLC now owns 10,910 shares of the company's stock valued at $301,000 after acquiring an additional 501 shares during the period. US Bancorp DE boosted its holdings in Myriad Genetics by 14.6% during the 1st quarter. US Bancorp DE now owns 4,243 shares of the company's stock valued at $108,000 after acquiring an additional 541 shares during the period. Finally, Arizona State Retirement System boosted its holdings in Myriad Genetics by 2.8% during the 1st quarter. Arizona State Retirement System now owns 21,586 shares of the company's stock valued at $544,000 after acquiring an additional 578 shares during the period. 97.44% of the stock is currently owned by hedge funds and other institutional investors.
Myriad Genetics Company Profile
(Get Rating)
Myriad Genetics, Inc, a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.
Recommended Stories
- Get a free copy of the StockNews.com research report on Myriad Genetics (MYGN)
- Home Depot, Lowe's On Track To Grow 2022 Earnings
- Could Smaller be Better for Investors in Norwegian Cruise Lines?
- Walmart Or Target: Which Is The Stronger Stock?
- Can Etsy Continue to Thrive After the Pandemic?
- MarketBeat Podcast: Investing in What You Know Has Changed
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.
